The difficult task of evaluating how to monitor patients with heart failure

Journal of Cardiac Failure

Volumn 11, Issue 6, 2005, Pages 422-424

  Tang, W H Wilson ^a,b   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BRADYCARDIA; CARDIOPULMONARY EXERCISE TEST; CELL HETEROGENEITY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; FUNCTIONAL STATUS; HEALTH STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; NOTE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33644597791     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2005.05.001     Document Type: Editorial

References (19)

1. B.M. Massie Heart failure trials: are they becoming impractical? J Card Fail 11 2005 161 163
2. R.J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 44 2004 740 749
3. J.A. Doust, P.P. Glasziou, E. Pietrzak, and A.J. Dobson A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure Arch Intern Med 164 2004 1978 1984
4. A.H. Wu, and A. Smith Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure Eur J Heart Fail 6 2004 355 358
5. S. Bruins, M.R. Fokkema, J.W. Romer, M.J. Dejongste, F.P. van der Dijs, and J.M. van den Ouweland High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure Clin Chem 50 2004 2052 2058
6. W.H. Tang, J.P. Girod, M.J. Lee, R.C. Starling, J.B. Young, and F. Van Lente Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure Circulation 108 2003 2964 2966
7. J.O. O'Neill, C.E. Bott-Silverman, A.T. McRae 3rd, R.W. Troughton, K. Ng, and R.C. Starling B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure Am Heart J 149 2005 363 369
8. H. Dokainish, W.A. Zoghbi, N.M. Lakkis, F. Al-Bakshy, M. Dhir, and M.A. Quinones Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters Circulation 109 2004 2432 2439
9. M.L. Rawlins, W.E. Owen, and W.L. Roberts Performance characteristics of four automated natriuretic peptide assays Am J Clin Pathol 123 2005 439 445
10. M. Ala-Kopsala, J. Magga, K. Peuhkurinen, J. Leipala, H. Ruskoaho, and J. Leppaluoto Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides Clin Chem 50 2004 1576 1588
11. J. Abdulla, L. Kober, and C. Torp-Pedersen Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods? Cardiovasc Drugs Ther 18 2004 219 224
12. A. Maisel, J.E. Hollander, D. Guss, P. McCullough, R. Nowak, and G. Green Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath J Am Coll Cardiol 44 2004 1328 1333
13. J.A. Spertus, J. Tooley, P. Jones, C. Poston, E. Mahoney, and P. Deedwania Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) Am Heart J 143 2002 636 642
14. S.A. Luther, P.A. McCullough, E.P. Havranek, J.S. Rumsfeld, P.G. Jones, and P.A. Heidenreich The relationship between B-type natriuretic peptide and health status in patients with heart failure J Card Fail 11 2005 414 421
15. J.A. Doust, E. Pietrzak, A. Dobson, and P. Glasziou How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ 330 2005 625
16. P. Jourdain, F. Funck, P. Gueffet, H. LeHelloco, E. Donal, and J.F. Aupetit Benefits of BNP plasma levels for optimizing therapy: the systolic heart failure treatment supported by BNP multicenter randomized trial (STARS-BNP) J Am Coll Cardiol 45 Suppl 2005 3A
17. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
18. P.J. Hauptman, F.A. Masoudi, W.S. Weintraub, I. Pina, P.G. Jones, and J.A. Spertus Variability in the clinical status of patients with advanced heart failure J Card Fail 10 2004 397 402
19. E.F. Lewis, P.A. Johnson, W. Johnson, C. Collins, L. Griffin, and L.W. Stevenson Preferences for quality of life or survival expressed by patients with heart failure J Heart Lung Transplant 20 2001 1016 1024